UP!

IMAX $17.15

IMAX target price
17.15
0
0
IMAX Corporation
Type
Public
Traded as NYSE: IMAX
Industry Motion picture production and exhibition
Predecessor Multi-Screen Corporation, IMAX Systems Corporation
Founded 1968; 49 years ago (1968) in Montreal, Quebec, Canada
Founders Graeme Ferguson
Roman Kroitor
Robert Kerr
William Shaw
Headquarters Mississauga, Ontario, Canada
Area served
Worldwide
Key people
Bradley Wechsler (Chairman)
Richard Gelfond (CEO)
Products Special-venue films and movie theatres
Revenue Increase US$2.095 billion (2016)
Profit Increase US$41.3 million (2012)
Total assets Increase US$421 million (2012)
Total equity Increase US$253 million (2012)
Number of employees
526
Divisions IMAX, IMAX 3D, IMAX Dome, IMAX DMR, IMAX at AMC (joint venture with AMC Theatres)
Subsidiaries Ridefilm Corporation
Sonics Associates
David Keighley Productions
3D Entertainment
Website www.imax.com

The IMAX Corporation is a Canadian theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post production and distribution to IMAX affiliated theatres worldwide. Founded in 1968, it has operations in Toronto, as well as New York City and Los Angeles.

As of June 2016, the IMAX theater network consisted of 1,102 theatres in 69 countries. These include IMAX variations such as IMAX 3D, IMAX Dome, and Digital IMAX.

IMAX is a Canadian corporation that is based in Toronto and Mississauga, Ontario. The Company was officially founded in 1967 when three filmmakers, Graeme Ferguson, Roman Kroitor and Robert Kerr incorporated IMAX Corporation. The idea and the new technology, which resulted in the birth of the company, came from the work that Ferguson, Kroitor and Kerr had done producing the multi-screen National Film Board of Canada production In the Labyrinth and Ferguson's Man and the Polar Regions for Expo 67. From their experience, Graeme Ferguson, Roman Kroitor and Robert Kerr realized that new technology would be necessary to develop a larger and more complex project than previously seen. As a result, they sought an engineer named William Shaw in 1968 (he had gone to Galt Collegiate Institute in Galt, Ontario, now Cambridge, with Ferguson and Kerr) to help develop this technology. Shaw created this new projector that allowed for films to have exceptionable quality and to be ten times larger than conventional 35mm picture frames. The first movie IMAX Corporation produced using this new technology was Tiger Child which was featured at Expo '70 in Osaka, Japan. It was because of the multi-screen viewing that Graeme Ferguson, Roman Kroitor and Robert Kerr wanted to create a theatre with giant screens, surround sound and stadium seating.

William Shaw was instrumental in helping IMAX Corporation fulfill its ambitions in creating larger and more realistic experiences for audience which included oversized screens, surround sound and steep seating for better viewing. Shaw remained at IMAX (although officially retired) as a designer and inventor until his passing on August 31, 2002 at the age of 73. Before retiring Shaw created a 3D camera which was sent to the International Space Station for IMAX films. Another engineer at IMAX Corporation Brian Bonnick, Chief Technology Officer at IMAX Corporation, developed technologies that made it possible for the worldwide IMAX to produce major Hollywood films. It was a critical point when IMAX Corporation sought to expand in 1994 by publicly listing IMAX on the NASDAQ stock exchange, and it became apparent then the future of the company rest in their ability to attract Hollywood production houses. To do this required flexible technology able to adapt quickly in various locations. Bonnick and his group created IMAX DMR (Digital Re-Mastering), which allowed for these requirements and paved the way for the large Hollywood blockbuster movies that would soon result. IMAX Corporation has gone on to expand with various new technologies including The IMAX Experience and the IMAX MPX theatre system and have also revamped IMAX 2D footage into IMAX 3D. The success of IMAX has made it possible for IMAX Corporation to sign deals with countries around the world. In 2009 IMAX Corporation signed a deal with China building the first ever IMAX theatre in Tianjin, China. The theatre was set to open in 2012. In March 2011 IMAX noted that China's Wanda Cinema Line announced a 75-theatre deal with IMAX Corporation. This was one of the largest international deals to the date of 2011 for IMAX and one of the second largest in Company History. While IMAX Corporation has expanded profoundly throughout the decades, it still sees itself as a leader in:

The Company motto is "IMAX IS BELIEVING", highlighting the original founder's philosophies of creating a real life like experience for the audience.

In 2011 IMAX, Discovery Communications and Sony announced to launch a 3D television channel; the companies later announced the upcoming channel would be named "3DNet". In August 2014 3DNet closed down due to low ratings.

On October 8, 2015, IMAX China, a subsidiary of the company, was listed on the Hong Kong Stock Exchange.

In November 2016, Marvel Television and IMAX announced the live action television series, Marvel's Inhumans, based on the superhero race of the same name. The series, co-produced with ABC Studios, saw IMAX serve as a financing partner, a first for IMAX, which allowed Marvel to spend more on the series than it had on its other television series, especially for visual effects. The entire series was filmed with IMAX digital cameras. Inhumans debuted an edited specific for theatrical-release version of the first two episodes. The episodes debuted on IMAX screens in theaters worldwide in September 2017, with the series airing weekly on ABC afterwards. After the poor reception to the IMAX version of the first two episodes and a box office gross of $3.5 million, Richard Gelfond said, "Going forward, we intend to take a more conservative approach consistent with the Game of Thrones approach to capital investments and content. We will be more conservative when considering whether to invest our own capital; and if so, to what extent."

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-10-26 Future report Set alerts
Q2 2022 2022-07-28 0.00 0.00
Q1 2022 2022-04-28 -0.14 -0.14
Q4 2021 2022-02-23 0.31 0.31
Q3 2021 2021-10-28 -0.08 -0.08
Q2 2021 2021-07-27 -0.12 -0.12
Q1 2021 2021-04-29 -0.25 -0.25
Q4 2020 2021-03-04 -0.21 -0.21
Q3 2020 2020-10-29 -0.75 -0.80
Q2 2020 2020-07-28 -0.44 -0.44

Ratings

2016-06-23 Reiterated Rating Stifel Nicolaus Buy $45.00
2016-06-22 Reiterated Rating Canaccord Genuity Buy
2016-06-22 Reiterated Rating Credit Suisse Buy
2016-06-22 Reiterated Rating Benchmark Co. Buy
2016-06-22 Reiterated Rating Credit Suisse Group AG Buy
2016-06-13 Reiterated Rating Stifel Nicolaus Buy $45.00
2016-06-12 Reiterated Rating B. Riley Buy $40.00
2016-06-07 Reiterated Rating B. Riley Buy $45.00 to $40.00
2016-05-26 Reiterated Rating Piper Jaffray Overweight $45.00
2016-05-26 Reiterated Rating Piper Jaffray Cos. Overweight $45.00
2016-05-25 Reiterated Rating Macquarie Outperform $43.00
2016-05-25 Reiterated Rating B. Riley Buy $45.00
2016-05-24 Reiterated Rating MKM Partners Buy $40.00
2016-05-24 Reiterated Rating Credit Suisse Buy
2016-05-20 Reiterated Rating Canaccord Genuity Buy
2016-05-12 Reiterated Rating Canaccord Genuity Buy
2016-04-29 Reiterated Rating B. Riley Buy $45.00
2016-04-25 Reiterated Rating Stifel Nicolaus Buy $45.00
2016-04-24 Reiterated Rating B. Riley Buy $45.00
2016-04-22 Boost Price Target MKM Partners Buy $39.00 to $40.00
2016-04-21 Reiterated Rating Wedbush Outperform $38.00 to $40.00
2016-04-21 Reiterated Rating Canaccord Genuity Buy $37.00
2016-04-19 Reiterated Rating B. Riley Buy $44.00
2016-04-06 Reiterated Rating MKM Partners Buy $39.00
2016-03-23 Reiterated Rating B. Riley Buy $44.00
2016-03-11 Reiterated Rating Canaccord Genuity Buy $37.00
2016-03-10 Reiterated Rating Piper Jaffray Buy $45.00
2016-03-07 Reiterated Rating Benchmark Co. Buy $40.78 to $43.58
2016-02-28 Reiterated Rating Canaccord Genuity Buy
2016-02-27 Reiterated Rating B. Riley Buy $44.00
2016-02-22 Reiterated Rating Canaccord Genuity Buy $43.00
2016-02-22 Upgrade Wedbush Neutral to Outperform $38.00
2016-02-22 Reiterated Rating B. Riley Buy $44.00
2016-02-22 Lower Price Target MKM Partners Buy $44.00 to $39.00
2016-02-22 Boost Price Target Benchmark Co. Buy $40.78
2016-02-21 Reiterated Rating Rosenblatt Securities Buy $47.00
2016-02-16 Lower Price Target Dougherty & Co Buy $50.00 to $40.00
2016-02-09 Lower Price Target JPMorgan Chase & Co. Neutral $37.00 to $30.00
2016-01-31 Reiterated Rating Canaccord Genuity Buy $43.00
2016-01-09 Reiterated Rating B. Riley Buy $52.00
2016-01-07 Lower Price Target JPMorgan Chase & Co. $40.00 to $37.00
2016-01-05 Reiterated Rating Rosenblatt Securities Buy $47.00
2016-01-03 Reiterated Rating B. Riley Buy $52.00
2016-01-03 Reiterated Rating MKM Partners Buy
2015-12-28 Reiterated Rating MKM Partners Buy $44.00
2015-12-22 Reiterated Rating Rosenblatt Securities Buy $47.00
2015-12-21 Reiterated Rating B. Riley Buy $52.00
2015-12-16 Reiterated Rating B. Riley Buy $52.00
2015-12-11 Reiterated Rating Canaccord Genuity Buy $43.00
2015-12-06 Reiterated Rating B. Riley Buy $52.00
2015-12-01 Reiterated Rating B. Riley Buy $52.00
2015-11-20 Reiterated Rating Goldman Sachs Neutral $39.00
2015-11-20 Reiterated Rating Goldman Sachs Group Inc. Neutral $39.00
2015-11-13 Reiterated Rating B. Riley Buy $52.00
2015-11-02 Boost Price Target Canaccord Genuity Buy $42.00 to $43.00
2015-10-30 Reiterated Rating B. Riley Buy $52.00
2015-10-29 Upgrade Wedbush Hold $38.00
2015-10-29 Boost Price Target MKM Partners Buy $44.00
2015-10-29 Boost Price Target Stifel Nicolaus Buy $40.00 to $45.00
2015-10-26 Reiterated Rating Canaccord Genuity Buy $42.00 to $43.00
2015-10-25 Reiterated Rating B. Riley Buy $52.00
2015-10-22 Reiterated Rating Wedbush Hold $38.00
2015-10-20 Boost Price Target Benchmark Co. Buy $40.78
2015-10-20 Reiterated Rating B. Riley Buy $53.00 to $52.00
2015-10-16 Lower Price Target Dougherty & Co Buy $52.00 to $50.00
2015-10-07 Reiterated Rating B. Riley Buy $53.00
2015-10-01 Reiterated Rating B. Riley Buy $53.00
2015-10-01 Reiterated Rating Canaccord Genuity Buy $42.00
2015-09-22 Reiterated Rating Piper Jaffray Buy
2015-09-22 Reiterated Rating Canaccord Genuity Buy $42.00
2015-09-15 Reiterated Rating Canaccord Genuity Buy $42.00
2015-09-09 Lower Price Target MKM Partners Buy $50.00 to $40.00
2015-09-09 Lower Price Target Stifel Nicolaus Buy $45.00 to $40.00
2015-09-07 Reiterated Rating B. Riley Buy $53.00
2015-09-02 Reiterated Rating B. Riley Buy $53.00
2015-07-30 Reiterated Rating B. Riley Buy $53.00
2015-07-25 Reiterated Rating B. Riley Buy $53.00
2015-07-21 Reiterated Rating Canaccord Genuity Buy $42.00
2015-07-20 Reiterated Rating B. Riley Buy $53.00
2015-07-17 Reiterated Rating MKM Partners Buy $50.00
2015-07-17 Reiterated Rating Wedbush Neutral $38.00
2015-07-13 Upgrade Piper Jaffray Neutral to Overweight $33.00 to $41.00
2015-07-04 Reiterated Rating B. Riley Buy $53.00
2015-06-29 Lower Price Target Evercore ISI $17.00 to $16.50
2015-06-29 Reiterated Rating B. Riley Buy $53.00
2015-06-26 Reiterated Rating Macquarie Outperform $46.00
2015-06-25 Reiterated Rating Stifel Nicolaus Buy $45.00
2015-06-25 Reiterated Rating RBC Capital Buy $42.00 to $47.00
2015-06-25 Reiterated Rating Royal Bank Of Canada Buy $42.00 to $47.00
2015-06-16 Reiterated Rating B. Riley Buy $50.00
2015-06-11 Reiterated Rating Stifel Nicolaus Buy $45.00
2015-06-11 Reiterated Rating RBC Capital Buy $42.00 to $47.00
2015-06-10 Set Price Target Canaccord Genuity Buy $45.00
2015-06-10 Boost Price Target Dougherty & Co Buy $42.00 to $52.00
2015-06-09 Reiterated Rating B. Riley Buy $50.00
2015-06-08 Boost Price Target MKM Partners Buy $42.00 to $50.00
2015-06-01 Boost Price Target Dougherty & Co Buy $42.00 to $52.00
2015-06-01 Reiterated Rating Credit Suisse Outperform $41.00 to $44.00
2015-05-29 Reiterated Rating Wedbush Neutral $38.00
2015-05-28 Set Price Target Stifel Nicolaus Buy $40.00 to $45.00
2015-05-28 Reiterated Rating B. Riley Buy $50.00
2015-05-28 Reiterated Rating Canaccord Genuity Buy $42.00
2015-05-09 Reiterated Rating Benchmark Co. Buy $38.20 to $41.77
2015-05-06 Reiterated Rating B. Riley Buy $50.00
2015-04-30 Reiterated Rating Canaccord Genuity Buy $38.00
2015-04-29 Reiterated Rating B. Riley Buy $40.00 to $50.00
2015-04-27 Set Price Target Benchmark Co. Buy $38.20 to $41.16
2015-04-27 Set Price Target Wedbush Hold $38.00
2015-04-23 Reiterated Rating MKM Partners Buy $40.00 to $42.00
2015-04-08 Upgrade Canaccord Genuity Buy
2015-04-06 Upgrade Canaccord Genuity Hold to Buy $35.00 to $38.00
2015-04-02 Set Price Target Stifel Nicolaus Buy $40.00
2015-04-02 Initiated Coverage Macquarie Outperform $39.00
2015-02-24 Reiterated Rating B. Riley Buy $43.50
2015-02-21 Reiterated Rating Dougherty & Co Buy $42.00
2015-02-20 Reiterated Rating Wedbush Neutral $30.00
2015-02-20 Boost Price Target Benchmark Co. Buy $34.49 to $38.20
2015-02-20 Boost Price Target Dougherty & Co Buy $38.00 to $42.00
2015-02-19 Set Price Target Stifel Nicolaus Buy $38.00
2015-02-19 Reiterated Rating B. Riley Buy $43.50
2015-02-17 Downgrade Canaccord Genuity Buy to Hold $34.50
2015-02-05 Downgrade JPMorgan Chase & Co. Overweight to Neutral $33.00 to $35.00
2015-01-27 Set Price Target B. Riley Buy $39.00
2015-01-26 Initiated Coverage Rosenblatt Securities Buy $38.00
2015-01-15 Boost Price Target MKM Partners Top Pick to Buy $34.00 to $36.00
2015-01-13 Set Price Target Canaccord Genuity Buy $34.50
2015-01-11 Reiterated Rating B. Riley Buy $39.00
2014-11-11 Upgrade Goldman Sachs Neutral to Buy $28.00 to $34.00
2014-09-15 Reiterated B. Riley & Co. Buy $32.50 to $39
2014-09-15 Boost Price Target B. Riley Buy $32.50 to $39.00
2014-07-28 Upgrade Benchmark Co. Buy
2014-07-25 Upgrade Benchmark Co. Hold to Buy
2014-07-24 Reiterated Rating Dougherty & Co Buy $38.00
2014-07-21 Upgrade B. Riley Neutral to Buy
2014-07-21 Upgrade Stifel Nicolaus Hold to Buy $32.00
2014-07-16 Downgrade Piper Jaffray Overweight to Neutral $35.00 to $28.00
2014-04-22 Reiterated Rating Wedbush Hold to Neutral $28.00
2014-02-20 Reiterated Dougherty & Company Buy $34 to $38
2014-02-20 Boost Price Target Dougherty & Co Buy $34.00 to $38.00
2014-02-04 Initiated Coverage CRT Capital Buy
2014-01-09 Boost Price Target Canaccord Genuity Buy $32.00 to $34.50
2013-12-19 Initiated Coverage Roth Capital Buy $32.00
2013-12-10 Initiated Coverage Ascendiant Capital Markets Buy $32.00
2013-12-03 Downgrade Goldman Sachs Buy to Neutral $29.96 to $30.00
2013-11-19 Boost Price Target MKM Partners Buy $32.00 to $34.00
2013-10-21 Reiterated Rating Sterne Agee CRT Hold $27.00
2013-10-21 Boost Price Target Benchmark Co. Hold $29.42 to $29.45
2013-10-03 Downgrade Cormark Market Perform to Reduce $23.00 to $22.00
2013-10-02 Initiated The Benchmark Company Hold $29.42
2013-10-02 Initiated Coverage Benchmark Co. Hold $29.42
2013-09-30 Reiterated Rating Sterne Agee CRT Neutral $28.00 to $27.00
2013-09-25 Reiterated B. Riley & Co. Buy $37 to $35.50
2013-09-25 Lower Price Target B. Riley Buy $37.00 to $35.50
2013-09-18 Boost Price Target MKM Partners Buy $30.00 to $34.00
2012-10-22 Initiated Hudson Square Research Buy $28
2012-09-13 Reiterated Barrington Research Outperform $29 to $27
2011-12-05 Upgrade Stifel Nicolaus Hold to Buy $25
2011-04-29 Reiterated Wedbush Outperform $35 to $40
2011-03-25 Upgrade Canaccord Genuity Hold to Buy $28.25 to $34
2011-02-22 Reiterated Wedbush Outperform $24 to $35
2011-01-05 Reiterated Morgan Joseph Buy $22 to $32
2010-10-29 Reiterated Barrington Research Outperform $24 to $28
2016-06-23 Reiterated Rating Stifel Nicolaus Buy $45.00
2016-06-22 Reiterated Rating Canaccord Genuity Buy
2016-06-22 Reiterated Rating Credit Suisse Buy
2016-06-22 Reiterated Rating Benchmark Co. Buy
2016-06-22 Reiterated Rating Credit Suisse Group AG Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks